


Faropenem daloxate

Chemical Properties

CAS No. :	141702-36-5
Formula:	C ₁₇ H ₁₉ N ₀ S
Molecular Weight:	397.4
Storage:	Store at low temperature Powder: -20°C for 3 years In solvent: -80°C for 1 year <i>Actual storage temperature shall be subject to the COA.</i>



Biological Description

Description	Faropenem daloxate (Faropenem medoxil) is useful for penem and antibiotics. Faropenem medoxomil has excellent in vitro activity against Streptococcus pneumoniae, Haemophilus influenzae and other key pathogens implicated in acute bacterial rhinosinusitis. Faropenem daloxate is the first oral penem in a new class of beta-lactam antibiotics.
Targets(IC50)	Antibacterial, Antibiotic

Solubility Information

Solubility	DMSO: ≥ 100 mg/mL (251.64 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.03 mM), Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.5164 mL	12.5818 mL	25.1636 mL
5 mM	0.5033 mL	2.5164 mL	5.0327 mL
10 mM	0.2516 mL	1.2582 mL	2.5164 mL
50 mM	0.0503 mL	0.2516 mL	0.5033 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Faqi AS, Lanphear C, Gill S, Colagiovanni DB. Juvenile toxicity study of faropenem medoxomil in beagle puppies. *Reprod Toxicol.* 2010 Dec;30(4):619-24. Epub 2010 Aug 11.
- Hadley JA, Tillotson GS, Tosiello R, Echols RM. Faropenem medoxomil: a treatment option in acute bacterial rhinosinusitis. *Expert Rev Anti Infect Ther.* 2006 Dec;4(6):923-37.
- Siegert R, Berg O, Gehanno P, Leiberman A, Martinkenas JL, Nikolaidis P, Arvis P, Alefelder M, Reimnitz P. Comparison of the efficacy and safety of faropenem daloxate and cefuroxime axetil for the treatment of acute bacterial maxillary sinusitis in adults. *Eur Arch Otorhinolaryngol.* 2003 Apr;260(4):186-94. Epub 2002 Oct 11.
- Upchurch J, Rosemore M, Tosiello R, Kowalsky S, Echols R. Randomized double-blind study comparing 7- and 10-day regimens of faropenem medoxomil with a 10-day cefuroxime axetil regimen for treatment of acute bacterial sinusitis. *Otolaryngol Head Neck Surg.* 2006 Oct;135(4):511-7.
- Gettig, Jacob P.; Crank, Christopher W.; Philbrik, Alexander H. Faropenem medoxomil. *Annals of Pharmacotherapy* (2008), 42(1), 80-90.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481